News >

CAR T-Cell Therapy Active in High-Risk, Refractory CLL

Published: Wednesday, Sep 20, 2017

Cameron J. Turtle, PhD

Cameron J. Turtle, PhD
Patients with refractory chronic lymphocytic leukemia (CLL) achieved a high-response rate with CD19-targeted CAR T-cell therapy, results of a small, single-arm study showed.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication